期刊文献+

米卡芬净等对抗白念珠菌生物膜的体外研究 被引量:2

In vitro activity of mieafungin against Candida albicans biofilms
原文传递
导出
摘要 目的探讨体外白念珠菌生物膜对米卡芬净的敏感性。方法通过建立白念珠菌生物膜的体外模型,用抗真菌药物敏感实验法和甲基四氮盐(XTT)减低法来评价白念珠菌生物膜对氟康唑、两性霉素B、米卡芬净的敏感性。结果30株白念珠菌生物膜中,所有菌株对氟康唑均耐药(SMIC80≥64μg/mL);4株对两性霉素B敏感(SMXC80≤1μg/mL),26株对两性霉素B耐药(MIC80〉1μg/mL);27株对米卡芬净敏感(SMIC80〈16μg/mL),3株对米卡芬净耐药(SMIC80≥16μg/mL)。经统计学分析,就白念珠菌生物膜的敏感性而言,米卡芬净和氟康唑之问差异有统计学意义(X2=736.36,P〈0.01),米卡芬净和两性霉素B之间差异有统计学意义(X2=529.95,P〈0.01),氟康唑和两性霉素B之间差异无统计学意义(矿=2.29,P〉0.05)。结论白念珠菌生物膜对目前常用的系统性抗真菌药物两性霉素B、氟康唑明显耐药,而对米卡芬净比较敏感。 Objective To explore the susceptibility of Candida albicans biofilms to micafungin. Methods In vitro model of C. albicans biofilm was established in 96-well microtiter plates with 30 C. albicans isolates from the Department of Mycology, Changhai Hospital, Shanghai. The susceptibility of C. albicans biofilms to fluconazole, amphotericine B and micafungin was evaluated by colorimetric XTT-reduction assay. Sessile MIC80 (SMIC80), defined as the lowest antifungal concentration at which an 80% reduction in fungal growth was achieved, was determined. Results Of the 30 C. albicans isolates grown in sessile states, all were resistant to fluconazole (SMIC80≥64μg/mL), 4 sensitive to amphotericine B (SMIC80 ≤ 1μg/mL), 26 resistant to amphotericine B (SMIC80 ≥ 1 μg/mL), 27 sensitive to micafungin (SMIC80 ≤ 16 μg/mL), 3 resistant to micafungin (SMIC80≥16 μg/mL). Statistical analysis revealed a significant difference in the activity against C. albicans biofilms between micafungin and fluconazole (X2= 736.36, P 〈 0.01), micafungin and amphotericine B (X2 = 529.95, P 〈 0.01 ), but not between anphotericine B and fluconazole 0f = 2.29, P 〉 0.05). Conclusion C.albicans biofilms are resistant to routine antifungal agents such as fluconazole and amphotericine B, but relatively more sensitive to micafungin.
出处 《中华皮肤科杂志》 CAS CSCD 北大核心 2009年第2期135-137,共3页 Chinese Journal of Dermatology
关键词 念珠菌 白色 生物膜 抗真菌药 Candida albicans Biofilms Antifungal agents
  • 相关文献

参考文献6

  • 1Douglas LJ. Candida biofilms and their role in infection. Trends Microbiol, 2003, 11 ( 1 ): 30-36.
  • 2Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev, 2002, 15 (2): 167-193.
  • 3Chandrasekar PH, Sobel JD. Micafungin: a new echinocandin. Clin Infect Dis, 2006, 42(8): 1171-1178.
  • 4Ramage G, Vande Walle K, Wickes BL, et al. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents Chemother, 2001, 45 (9): 2475-2479.
  • 5Kuhn DM, Balkis M, Chandra J, et al. Uses and limitations of the XTT assay in studies of Candida growth and metabolism. J Clin Microbiol, 2003, 41 (1): 506-508.
  • 6Messer SA, Diekema D J, Boyken L, et al. Activities of Micafungin against 315 Invasive Clinical Isolates of Fluconazole-Resistant Canchida spp. J Clin Microbiol, 2006, 44(2): 324-326.

同被引文献32

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部